14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 6 May 2024

Trading levels for CARA

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 0.82 5.01 %
R2 0.80 3.06 %
R1 0.793 1.85 %
Current price: 0.778
Support S1 0.762 -2.06 %
S2 0.753 -3.26 %
S3 0.738 -5.22 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0.91 16.94 %
R2 0.91 16.56 %
R1 0.80 2.94 %
Current price 0.778
Support S1 0.730 -6.17%
S2 0.709 -8.89%
S3 0.595 -23.50%

CARA Predictions History

7 years ago
Charlie.Martin.2040 predicted that CARA for 2016-12-29 is going $11.07 (12.61%)

Rank:

7 years ago
AJR predicted that CARA for 2016-12-05 is going $9.33 (-1.79%)

Rank:

7 years ago
Abdu predicted that CARA for 2016-12-05 is going $9.31 (-2.00%)

7 years ago
JS predicted that CARA for 2016-12-05 is going $10.02 (5.47%)

7 years ago
Mel.Ah.1743 predicted that CARA for 2016-12-05 is going $10.20 (7.37%)

Rank:

7 years ago
Abdu predicted that CARA for 2016-11-28 is going $9.89 (7.27%)

7 years ago
JS predicted that CARA for 2016-11-28 is going $9.46 (-3.76%)

7 years ago
Abdu predicted that CARA for 2016-11-17 is going $12.71 (8.63%)

7 years ago
JS predicted that CARA for 2016-11-17 is going $11.02 (-5.81%)

7 years ago
Steve.Sullivan.925 predicted that CARA for 2016-11-10 is going $10.02 (7.05%)

Rank:
Click to get the best stock tips daily for free!

About Cara Therapeutics

Cara Therapeutics Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of mod... CARA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT